Can remission be maintained with or without further drug therapy in rheumatoid arthritis?

Clinical and Experimental Rheumatology

Volumn 24, Issue 6 SUPPL. 43, 2006, Pages

  Saleem, Benazir ^a   Nizam, Sharmin ^a   Emery, Paul ^a  

^a CHAPEL ALLERTON HOSPITAL   (United Kingdom)

Author keywords

DMARDs; Remission; Rheumatoid arthritis; TNF antagonist therapy; Withdrawal of therapy

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; GOLD; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; PENICILLAMINE; PREDNISOLONE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE;

CLINICAL TRIAL; DISEASE CONTROL; DISEASE COURSE; DISEASE EXACERBATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; HUMAN; JOINT DESTRUCTION; JOINT RADIOGRAPHY; JOINT SWELLING; MONOTHERAPY; MORNING STIFFNESS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT REFERRAL; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SYNOVITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION SCHEDULE; ENDPOINT DETERMINATION; HUMANS; RANDOMIZED CONTROLLED TRIALS; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TERMINOLOGY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33750695330     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. van der HEIDJE DM: Judging disease activity in clinical practise in rheumatoid arthritis. First step in the development of a disease activity score. Ann Rheum Dis 1990; 49: 916-20.
2. PREVOO ML, van GESTEL AM, van't HOF MA, van RIJSWIJK MH, van de PUTTE LB, van RIEL PL: Remission in a prospective study of patients with rheumatoid arthritis. ARA preliminary remission criteria in relation to disease activity score. Br J Rheumatol 1996; 36: 729-40.
3. PINALS RS, MASI AT, LARSEN RA: Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981; 24: 1308-15.
4. BALSA A, CARMONA L, GONZALEZ-ALVARO I, BELMONTE MA, TENA X, SANMARTI R: EMECAR Study Group. Value of Disease Activity Score 28 (DAS28) and DAS28-3 compared to American College of Rheumatology-defined remission in rheumatoid arthritis. J Rheumatol 2004; 31: 40-6.
5. LANDEWE RB, van der HEIJDE DM, BOERS M: 28-joint counts invalidate the das28-remission definition due to the omission of the lower extremity joints: A comparison with the original das-remission. Ann Rheum Dis 2005. (Epub ahead of print.)
6. MAKINEN H, KAUTIAINEN H, HANNONEN P, SOKKA T: Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? Ann Rheum Dis 2005 Oct; 64: 1410-3.
7. ALETAHA D, WARD MM, MACHOLD KP, NELL VP, STAMM T, SMOLEN JS: Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum 2005; 52: 2625-36.
8. FRANSEN J, van RIEL PL: The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 2005; 23 (Suppl. 39): S93-9.
9. KRISHNAN E, HÄKKINEN A, SOKKA T, HANNONEN P: Impact of age and comorbidities on the criteria for remission and response in rheumatoid arthritis. Ann Rheum Dis 2005; 64: 1350-2.
10. MÖTTÖNEN T, HANNONEN P, LEIRISALO-REPO M et al.: Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FINRACo trial group. Lancet 1999; 353: 1568-73.
11. O'DELL JR, HAIRS CE, ERIKSON N et al.: Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996; 334: 1287-91.
12. TUGWELL P, PINCUS T, YOCUM D et al.: Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med 1995; 333: 137-41.
13. van der HEIJDE DM: Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol 1995; 34: 74-8.
14. SCOTT DL, SMITH C, KINGLEY G: Joint damage and disability in rheumatoid arthritis;an updated systematic review. Clin Exp Rheumatol 2003; 21 (Suppl. 31): S20-7.
15. SCOTT DL, PUGNER K, KAREELA K et al.: The links between joint damage and disability in rheumatoid arthritis. Rheumatology 2000; 39: 122-32.
16. EMERY P: Prognosis in inflammatory arthritis: the value of HLA genotyping and oncological analogy. J Rheumatol 1997; 24: 1436-42.
17. BOERS M: Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum 2003; 48: 1771-4.
18. QUINN MA, EMERY P: Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. N Engl J Med 2003; 21 (5 Suppl. 31): S154-7.
19. LIANG GC, CORDERO M, DYER A, CHANG RW: Current tumor necrosis factor-alpha inhibitor use is associated with a higher probability of remissions in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 1662-5.
20. DE SILVA M, HAZLEMAN BL: Long-term azathioprine in rheumatoid arthritis: a double-blind study. Ann Rheum Dis 1981; 40: 560-3.
21. CADE R, STEIN G, PICKERING M, SCHLEIN E, SPOONER G: Low dose, long-term treatment of rheumatoid arthritis with azathioprine. South Med J 1976; 69: 388-92.
22. AHERN MJ, HALL ND, CASE K, MADDISON PJ: D-penicillamine withdrawal in rheumatoid arthritis. Ann Rheum Dis 1984; 43: 213-7.
23. KREMER JM, RYNES RI, BARTHOLOMEW LE: Severe flare of rheumatoid arthritis after discontinuation of long-term methotrexate therapy. Double-blind study. Am J Med 1987; 82: 781-6.
24. SZANTO E: Low-dose methotrexate in rheumatoid arthritis: effect and tolerance. An open trial and a double-blind randomized study. Scand J Rheumatol 1986; 15: 97-102.
25. CATS A: A multicentre controlled trial of the effects of different dosage of gold therapy, followed by a maintenance dosage. Agents Actions 1976; 6: 355-63.
26. TEN WOLDE S, BREEDVELD FC, HERMANS J et al.: Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet 1996; 347: 347-52.
27. TEN WOLDE S, HERMANS J, BREEDVELD FC, DUKMANS BA: Effect of resumption of second line drugs in patients with rheumatoid arthritis that flared up after treatment discontinuation. Ann Rheum Dis 1997; 56: 235-9.
28. BROWN et al.: The longitudinal evaluation of RA patients in clinical remission: frequency of persistent remission, disease flare, structural and functional status. Arthritis Rheum 2005; 52: S122.
29. EMERY P, SALMON M: Early rheumatoid arthritis: time to aim for remission? Ann Rheum Dis 1995; 54: 944-7.
30. EMERY P, BREEDVELD FC, DOUGADOS M, KALDEN JR, SCHIFF MH, SMOLEN JS: Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 2002; 61: 290-7.
31. GREEN M, MARZO-ORTEGA H, McGONAGLE D et al.: Persistence of mild, early inflammatory arthritis: the importance of disease duration, rheumatoid factor, and the shared epitope. Arthritis Rheum 1999; 42: 2184-8.
32. SVENSSON B, BOONEN A, ALBERTSSON K, van der HEIJDE DM, KELLER C, HAFSTRÖM I for the BARFOT STUDY GROUP: Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: A two-year randomized trial. Arthritis Rheum 2005; 52: 3360-70.
33. QUINN MA, CONAGHAN PG, O'CONNOR PJ et al.: Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52: 27-35.
34. GOEKOOP-RUITERMAN YP, DE VRIES-BOUWSTRA JK, ALLAART CF et al.: Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52: 3381-90.
35. van der BIJL AE, GOEKOOP-RUITERMAN YP, BREEDVELD FC et al.: Initial combination therapy with infliximab and methotrexate can suppress rheumatoid arthritis activity after infliximab discontinuation. Arthritis Rheum 2005; 52 (Suppl.): S346.
36. EMERY P: Treatment of rheumatoid arthritis. BMJ 2006; 332: 152-5.